An Update on the Use of Immunomodulators in Primary Immunodeficiencies

Clinical Reviews in Allergy and Immunology

Volumn 52, Issue 2, 2017, Pages 287-303

  Vignesh, Pandiarajan ^a   Rawat, Amit ^a   Singh, Surjit ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Autoinflammatory disorders; Immunomodulators; Monoclonal antibodies; Primary immunodeficiencies

Indexed keywords

ABATACEPT; ALEMTUZUMAB; ALPHA INTERFERON; ANAKINRA; BETA INTERFERON; CANAKINUMAB; COMPLEMENT COMPONENT C1S INHIBITOR; ECULIZUMAB; ETANERCEPT; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 17 ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLATE MOFETIL; PEGADEMASE; PIOGLITAZONE; RAPAMYCIN; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 7; RHO KINASE INHIBITOR; RILONACEPT; RITUXIMAB; RUXOLITINIB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ANTIBODY; IMMUNOLOGIC FACTOR;

ANGIONEUROTIC EDEMA; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; AUTOINFLAMMATORY DISEASE; CHRONIC GRANULOMATOUS DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG USE; ENZYME REPLACEMENT; GRANULOMATOSIS; HEMOPHAGOCYTIC SYNDROME; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOREGULATION; IPEX SYNDROME; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; REVIEW; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; WISKOTT ALDRICH SYNDROME; ANIMAL; IMMUNOLOGIC DEFICIENCY SYNDROMES;

ANIMALS; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGIC FACTORS;

EID: 84996565809     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-016-8591-2     Document Type: Review

References (121)

1. Al-Herz W, Bousfiha A, Casanova J-L, Chatila T, Conley ME, Cunningham-Rundles C, Etzioni A, Franco JL, Gaspar HB, Holland SM, Klein C, Nonoyama S, Ochs HD, Oksenhendler E, Picard C, Puck JM, Sullivan K, Tang ML (2014) Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol 5:162. doi:10.3389/fimmu.2014.00162
2. Aguilar C, Malphettes M, Donadieu J, Chandesris O, Coignard-Biehler H, Catherinot E, Pellier I, Stephan JL et al (2014) Prevention of infections during primary immunodeficiency. Clin Infect Dis 59(10):1462–1470. doi:10.1093/cid/ciu646
3. Atkinson TP (2012) Immune deficiency and autoimmunity. Curr Opin Rheumatol 24(5):515–521. doi:10.1097/BOR.0b013e32835680c6
4. Griffith LM, Cowan MJ, Notarangelo LD, Puck JM, Buckley RH, Candotti F, Conley ME, Fleisher TA, Gaspar HB, Kohn DB, Ochs HD, O’Reilly RJ, Rizzo JD, Roifman CM, Small TN, Shearer WT (2009) Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management. J Allergy Clin Immunol 124(6):1152–1160. doi:10.1016/j.jaci.2009.10.022e12
5. Booth C, Gaspar HB, Thrasher AJ (2011) Gene therapy for primary immunodeficiency. Curr Opin Pediatr 23(6):659–666. doi:10.1097/MOP.0b013e32834cd67a
6. Chapel H, Prevot J, Gaspar HB, Español T, Bonilla FA, Solis L, Drabwell J (2014) Primary immune deficiencies—principles of care. Front Immunol 5:627. doi:10.3389/fimmu.2014.00627
7. ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, Cantarini L, Galeotti C, Grateau G, Hentgen V, Hofer M, Kallinich T et al (2015) Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis 74(9):1636–1644. doi:10.1136/annrheumdis-2015-207546
8. Federici S, Sormani MP, Ozen S, Lachmann HJ, Amaryan G, Woo P, Koné-Paut I, Dewarrat N, Cantarini L, Insalaco A, Uziel Y, Rigante D (2015) Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Ann Rheum Dis 74(5):799–805. doi:10.1136/annrheumdis-2014-206580
9. Masters SL, Simon A, Aksentijevich I, Kastner DL (2009) Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol 27:621–668. doi:10.1146/annurev.immunol.25.022106.141627
10. Grateau G, Hentgen V, Stojanovic KS, Jéru I, Amselem S, Steichen O (2013) How should we approach classification of autoinflammatory diseases? Nat Rev Rheumatol 9(10):624–629. doi:10.1038/nrrheum.2013.101
11. Almeida de Jesus A, Goldbach-Mansky R (2013) Monogenic autoinflammatory diseases: concept and clinical manifestations. Clin Immunol 147(3):155–174. doi:10.1016/j.clim.2013.03.016
12. Chinen J, Notarangelo LD, Shearer WT (2015) Advances in basic and clinical immunology in 2014. J Allergy Clin Immunol 135(5):1132–1141. doi:10.1016/j.jaci.2015.02.037
13. Maglione PJ, Simchoni N, Cunningham-Rundles C (2015) Toll-like receptor signaling in primary immune deficiencies. Ann N Y Acad Sci 1356:1–21. doi:10.1111/nyas.12763
14. Netea MG, Wijmenga C, O’Neill LAJ (2012) Genetic variation in Toll-like receptors and disease susceptibility. Nat Immunol 13(6):535–542. doi:10.1038/ni.2284
15. Perales-Linares R, Navas-Martin S (2013) Toll-like receptor 3 in viral pathogenesis: friend or foe? Immunology 140(2):153–167. doi:10.1111/imm.12143
16. Lafaille FG, Pessach IM, Zhang S-Y, Ciancanelli MJ, Herman M, Abhyankar A, Ying SW, Keros S, Goldstein PA, Mostoslavsky G, Ordovas-Montanes J, Jouanguy E et al (2012) Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells. Nature 491(7426):769–773. doi:10.1038/nature11583
17. The International Chronic Granulomatous Disease Cooperative Study Group (1991) A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 324(8):509–516. doi:10.1056/NEJM19910221324080
18. Weening RS, Leitz GJ, Seger RA (1995) Recombinant human interferon-gamma in patients with chronic granulomatous disease—European follow up study. Eur J Pediatr 154(4):295–298. doi:10.1007/BF01957365
19. Holland SM, Chronic granulomatous disease (2010) Clin Rev Allergy Immunol 38(1):3–10. doi:10.1007/s12016-009-8136-z
20. Bemiller LS, Roberts DH, Starko KM, Curnutte JT (1995) Safety and effectiveness of long-term interferon gamma therapy in patients with chronic granulomatous disease. Blood Cells Mol Dis 21(3):239–247. doi:10.1006/bcmd.1995.0028
21. Marciano BE, Wesley R, De Carlo ES, Anderson VL, Barnhart LA, Darnell D, Malech HL, Gallin JI, Holland SM (2004) Long-term interferon-gamma therapy for patients with chronic granulomatous disease. Clin Infect Dis 39(5):692–699. doi:10.1086/422993
22. Ahlin A, Elinder G, Palmblad J (1997) Dose-dependent enhancements by interferon-gamma on functional responses of neutrophils from chronic granulomatous disease patients. Blood 89(9):3396–3401
23. Naderi beni F, Fattahi F, Mirshafiey A, Ansari M, Mohsenzadegan M, Movahedi M, Pourpak Z, Moin M (2012) Increased production of nitric oxide by neutrophils from patients with chronic granulomatous disease on interferon-gamma treatment. Int Immunopharmacol 12(4):689–693. doi:10.1016/j.intimp.2012.01.016
24. Errante PR, Frazão JB, Condino-Neto A (2008) The use of interferon-gamma therapy in chronic granulomatous disease. Recent Pat Antiinfect Drug Discov 3(3):225–230. doi:10.2174/157489108786242378
25. Filiz S, Uygun DFK, Köksoy S, Şahin E, Yeğin O (2015) In vitro interferon γ improves the oxidative burst activity of neutrophils in patients with chronic granulomatous disease with a subtype of gp91phox deficiency. Cent Eur J Immunol 40(1):54–60. doi:10.5114/ceji.2015.50833
26. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V (2004) Autophagy is a defense mechanism inhibiting BCG and mycobacterium tuberculosis survival in infected macrophages. Cell 119(6):753–766. doi:10.1016/j.cell.2004.11.038
27. Singh SB, Davis AS, Taylor GA, Deretic V (2006) Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science 313(5792):1438–1441. doi:10.1126/science.1129577
28. Sharma VK, Pai G, Deswarte C, Lodha R, Singh S, Kang LW, Yin CC, Casanova JL, Bustamante J, Kabra SK (2015) Disseminated Mycobacterium avium complex infection in a child with partial dominant interferon gamma receptor 1 deficiency in India. J Clin Immunol 35(5):459–462. doi:10.1007/s10875-015-0173-1
29. Takeda K, Kawai T, Nakazawa Y, Komuro H, Shoji K, Morita K, Katsuta T, Yamamoto M, Miyairi I, Ohya Y, Ishiguro A, Onodera M (2014) Augmentation of antitubercular therapy with IFNγ in a patient with dominant partial IFNγ receptor 1 deficiency. Clin Immunol 151(1):25–28. doi:10.1016/j.clim.2014.01.004
30. Alangari AA, Al-Zamil F, Al-Mazrou A, Al-Muhsen S, Boisson-Dupuis S, Awadallah S, Kambal A, Casanova JL (2011) Treatment of disseminated mycobacterial infection with high-dose IFN-γ in a patient with IL-12Rβ1 deficiency. Clin Dev Immunol 2011:691956. doi:10.1155/2011/691956
31. Sheikh V, Porter BO, DerSimonian R, Kovacs SB, Thompson WL, Perez-Diez A, Freeman AF, Roby G, Mican J, Pau A, Rupert A, Adelsberger J et al (2016) Administration of interleukin-7 increases CD4 T cells in idiopathic CD4 lymphocytopenia. Blood 127(8):977–988. doi:10.1182/blood-2015-05-645077
32. Azuma H, Sakata H, Saijyou M, Okuno A (1993) Effect of interleukin 2 on intractable herpes virus infection and chronic eczematoid dermatitis in a patient with Wiskott-Aldrich syndrome. Eur J Pediatr 152(12):998–1000
33. Azuma H, Oshima M, Ito K, Okuno A, Kawabata I, Banba K, Murahashi H, Sekine T, Kato Y, Ikebuchi K, Ikeda H (2000) Impaired interleukin-2 production in T-cells from a patient with Wiskott-Aldrich syndrome: basis of clinical effect of interleukin-2 replacement therapy. Eur J Pediatr 159(8):633–634
34. Orange JS, Roy-Ghanta S, Mace EM, Maru S, Rak GD, Sanborn KB, Fasth A, Saltzman R, Paisley A, Monaco-Shawver L, Banerjee PP, Pandey R (2011) IL-2 induces a WAVE2-dependent pathway for actin reorganization that enables WASp-independent human NK cell function. J Clin Invest 121(4):1535–1548. doi:10.1172/JCI44862
35. Myrup B, Valerius NH, Mortensen PB (1998) Treatment of enteritis in chronic granulomatous disease with granulocyte colony stimulating factor. Gut 42(1):127–130
36. Wang J, Mayer L, Cunningham-Rundles C (2005) Use of GM-CSF in the treatment of colitis associated with chronic granulomatous disease. J Allergy Clin Immunol 115(5):1092–1094. doi:10.1016/j.jaci.2005.01.016
37. Ter Haar NM, Frenkel J (2014) Treatment of hereditary autoinflammatory diseases. Curr Opin Rheumatol 26(3):252–258. doi:10.1097/BOR.0000000000000059
38. Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, Laxer R, Tedgard U, Cowen EW, Pham TH, Booty M, Estes JD et al (2009) An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 360(23):2426–2437. doi:10.1056/NEJMoa0807865
39. Goldbach-Mansky R (2012) Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1. Clin Exp Immunol 167(3):391–404. doi:10.1111/j.1365-2249.2011.04533.x
40. Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, Hanrahan PS, Kraishi MM, Patel A, Sun G, Bear MB (2004) A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 63(9):1062–1068. doi:10.1136/ard.2003.016014
41. Hoffman HM, Throne ML, Amar NJ, Cartwright RC, Kivitz AJ, Soo Y, Weinstein SP (2012) Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther 34(10):2091–2103. doi:10.1016/j.clinthera.2012.09.009
42. Goldbach-Mansky R, Shroff SD, Wilson M, Snyder C, Plehn S, Barham B, Pham TH, Pucino F, Wesley RA, Papadopaulos JH, Weinstein SP, Mellis SJ, Kastner DL (2008) A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 58(8):2432–2442. doi:10.1002/art.23620
43. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins PN (2009) Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360(23):2416–2425. doi:10.1056/NEJMoa0810787
44. de Luca A, Smeekens SP, Casagrande A, Iannitti R, Conway KL, Gresnigt MS, Begun J, Plantinga TS, Joosten LA, van der Meer JW, Chamilos G, Netea MG et al (2014) IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. Proc Natl Acad Sci U S A 111(9):3526–3531. doi:10.1073/pnas.1322831111
45. van de Veerdonk FL, Netea MG, Dinarello CA, van der Meer JWM (2011) Anakinra for the inflammatory complications of chronic granulomatous disease. Neth J Med 69(2):95
46. Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, Bulashevska A, Petersen BS, Schaffer AA, Gruning BA, Unger S, Frede N et al (2014) Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med 20(12):1410–1416. doi:10.1038/nm.3746
47. Lee S, Moon JS, Lee C-R, Kim H-E, Baek S-M, Hwang S, Kang GH, Seo JK, Shin CH, Kang HJ, Ko JS, Park SG, Choi M (2016) Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4. J Allergy Clin Immunol 137(1):327–330. doi:10.1016/j.jaci.2015.08.036
48. Lo B, Zhang K, Lu W, Zheng L, Zhang Q, Kanellopoulou C, Zhang Y, Liu Z, Fritz JM, Marsh R, Husami A, Kissell D et al (2015) AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science 349(6246):436–440. doi:10.1126/science.aaa1663
49. Alkhairy OK, Abolhassani H, Rezaei N, Fang M, Andersen KK, Chavoshzadeh Z, Mohammadzadeh I, El-Rajab MA, Massaad M, Chou J, Aghamohammadi A, Geha RS et al (2016) Spectrum of phenotypes associated with mutations in LRBA. J Clin Immunol 36(1):33–45. doi:10.1007/s10875-015-0224-7
50. Hajishengallis G, Moutsopoulos NM (2016) Role of bacteria in leukocyte adhesion deficiency-associated periodontitis. Microb Pathog 94:21–26. doi:10.1016/j.micpath.2015.09.003
51. Moutsopoulos NM, Konkel J, Sarmadi M, Eskan MA, Wild T, Dutzan N, Abusleme L, Zenobia C, Hosur KB, Abe T, Uzel G, Chen W et al (2014) Defective neutrophil recruitment in leukocyte adhesion deficiency type I disease causes local IL-17-driven inflammatory bone loss. Sci Transl Med 6(229):229ra40. doi:10.1126/scitranslmed.3007696
52. Teachey DT (2014) Targeting cytokines in ALPS: it’s FAShionable. Blood 123(8):1116–1118. doi:10.1182/blood-2014-01-546713
53. Milner JD, Vogel TP, Forbes L, Ma CA, Stray-Pedersen A, Niemela JE, Lyons JJ, Engelhardt KR, Zhang Y, Topcagic N, Roberson ED, Matthews H et al (2015) Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood 125(4):591–599. doi:10.1182/blood-2014-09-602763
54. Wienke J, Janssen W, Scholman R, Spits H, van Gijn M, Boes M, van Montfrans J, Moes N, de Roock S (2015) A novel human STAT3 mutation presents with autoimmunity involving Th17 hyperactivation. Oncotarget 6(24):20037–20042. doi:10.18632/oncotarget.5042
55. Crow YJ, Vanderver A, Orcesi S, Kuijpers TW, Rice GI (2014) Therapies in Aicardi-Goutières syndrome. Clin Exp Immunol 175(1):1–8. doi:10.1111/cei.12115
56. Put K, Avau A, Brisse E, Mitera T, Put S, Proost P, Bader-Meunier B, Westhovens R, Van den Eynde BJ, Orabona S, Fallarino F, De Somer L et al (2015) Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ. Rheumatology (Oxford) 54(8):1507–1517. doi:10.1093/rheumatology/keu524
57. Jordan MB, Hildeman D, Kappler J, Marrack P (2004) An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 104(3):735–743. doi:10.1182/blood-2003-10-3413
58. Bracaglia C, Gatto A, Pardeo M, Lapeyre G, Ferlin W, Nelson R, de Min C, De Benedetti F (2015) Anti interferon-gamma (IFNγ) monoclonal antibody treatment in a patient carrying an NLRC4 mutation and severe hemophagocytic lymphohistiocytosis. Pediatr Rheumatol Online J 13(Suppl 1):O68. doi:10.1186/1546-0096-13-S1-O68
59. Bulua AC, Mogul DB, Aksentijevich I, Singh H, He DY, Muenz LR, Ward MM, Yarboro CH, Kastner DL, Siegel RM, Hull KM (2012) Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum 64(3):908–913. doi:10.1002/art.33416
60. Franxman TJ, Howe LE, Baker JR (2014) Infliximab for treatment of granulomatous disease in patients with common variable immunodeficiency. J Clin Immunol 34(7):820–827. doi:10.1007/s10875-014-0079-3
61. Marks DJB, Miyagi K, Rahman FZ, Novelli M, Bloom SL, Segal AW (2009) Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn’s disease. Am J Gastroenterol 104(1):117–124. doi:10.1038/ajg.2008.72
62. Uzel G, Orange JS, Poliak N, Marciano BE, Heller T, Holland SM (2010) Complications of tumor necrosis factor-α blockade in chronic granulomatous disease-related colitis. Clin Infect Dis 51(12):1429–1434. doi:10.1086/657308
63. Chase NM, Verbsky JW, Hintermeyer MK, Waukau JK, Tomita-Mitchell A, Casper JT, Singh S, Shahir KS, Tisol WB, Nugent ML, Rao RN, Mackinnon AC et al (2013) Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID). J Clin Immunol 33(1):30–39. doi:10.1007/s10875-012-9755-3
64. Boursiquot J-N, Gérard L, Malphettes M, Fieschi C, Galicier L, Boutboul D, Borie R, Viallard JF, Soulas-Sprauel P, Berezne A, Jaccard A, Hachulla E et al (2013) Granulomatous disease in CVID: retrospective analysis of clinical characteristics and treatment efficacy in a cohort of 59 patients. J Clin Immunol 33(1):84–95. doi:10.1007/s10875-012-9778-9
65. Gobert D, Bussel JB, Cunningham-Rundles C, Galicier L, Dechartres A, Berezne A, Bonnotte B, DeRevel T, Auzary C, Jaussaud R, Larroche C, LeQuellec A et al (2011) Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. Br J Haematol 155(4):498–508. doi:10.1111/j.1365-2141.2011.08880.x
66. Kim JJ, Thrasher AJ, Jones AM, Davies EG, Cale CM (2007) Rituximab for the treatment of autoimmune cytopenias in children with immune deficiency. Br J Haematol 138(1):94–96. doi:10.1111/j.1365-2141.2007.06616.x
67. Toyoda H, Azuma E, Kawasaki Y, Iwasa T, Ohashi H, Otsuki S, Iwamoto S, Hirayama M, Itoh-Habe N, Wada H, Kondo M, Keida Y, Ito T, Komada Y (2013) Cord blood transplantation combined with rituximab for Wiskott-Aldrich syndrome with autoimmune thrombotic thrombocytopenic purpura. J Allergy Clin Immunol 132(1):226–227. doi:10.1016/j.jaci.2013.01.040
68. Emir S, Vezir E, Azkur D, Demir HA, Metin A (2013) Characteristics of children with non-hodgkin lymphoma associated with primary immune deficiency diseases: descriptions of five patients. Pediatr Hematol Oncol 30(6):544–553. doi:10.3109/08880018.2013.792893
69. Sebire NJ, Haselden S, Malone M, Davies EG, Ramsay AD (2003) Isolated EBV lymphoproliferative disease in a child with Wiskott-Aldrich syndrome manifesting as cutaneous lymphomatoid granulomatosis and responsive to anti-CD20 immunotherapy. J Clin Pathol 56(7):555–557. doi:10.1136/jcp.56.7.555
70. Teachey DT (2012) New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome. Curr Opin Pediatr 24(1):1–8. doi:10.1097/MOP.0b013e32834ea739
71. Browne SK, Zaman R, Sampaio EP, Jutivorakool K, Rosen LB, Ding L, Pancholi MJ, Yang LM, Priel DL, Uzel G, Freeman AF, Hayes CE et al (2012) Anti-CD20 (rituximab) therapy for anti–IFN-γ autoantibody–associated nontuberculous mycobacterial infection. Blood 119(17):3933–3939. doi:10.1182/blood-2011-12-395707
72. Rosen LB, Freeman AF, Yang LM, Jutivorakool K, Olivier KN, Angkasekwinai N, Suputtamongkol Y, Bennett JE, Pyrgos V, Williamson PR, Ding L, Holland SM et al (2013) Anti-granulocyte-macrophage colony stimulating factor autoantibodies in patients with cryptococcal meningitis. J Immunol 190(8):3959–3966. doi:10.4049/jimmunol.1202526
73. Gavanescu I, Benoist C, Mathis D (2008) B cells are required for Aire-deficient mice to develop multi-organ autoinflammation: a therapeutic approach for APECED patients. Proc Natl Acad Sci U S A 105(35):13009–13014. doi:10.1073/pnas.0806874105
74. Beerli RR, Bauer M, Fritzer A, Rosen LB, Buser RB, Hanner M, Maudrich M, Nebenfuehr M, Toepfer JAS, Mangold S, Bauer A, Holland SM et al (2014) Mining the human autoantibody repertoire: isolation of potent IL17A-neutralizing monoclonal antibodies from a patient with thymoma. MAbs 6(6):1608–1620. doi:10.4161/mabs.36292
75. Branellec A, Bouillet L, Javaud N, Mekinian A, Boccon-Gibod I, Blanchard-Delaunay C, Oksenhendler E, Ollivier Y, Dunogué B, Amarger S, Ponard D, Drouet C et al (2012) Acquired C1-inhibitor deficiency: 7 patients treated with rituximab. J Clin Immunol 32(5):936–941. doi:10.1007/s10875-012-9691-2
76. Lionet A, Provôt F, Glowacki F, Frémeaux-Bacchi V, Hazzan M (2009) A case of adult atypical haemolytic uraemic syndrome related to anti-factor H autoantibodies successfully treated by plasma exchange, corticosteroids and rituximab. NDT Plus 2(6):458–460. doi:10.1093/ndtplus/sfp109
77. Czaja CA, Merkel PA, Chan ED, Lenz LL, Wolf ML, Alam R, Frankel SK, Fischer A, Gogate S, Perez-Velez CM, Knight V (2014) Rituximab as successful adjunct treatment in a patient with disseminated nontuberculous mycobacterial infection due to acquired anti-interferon-γ autoantibody. Clin Infect Dis 58(6):e115–e118. doi:10.1093/cid/cit809
78. Sinha A, Gulati A, Saini S, Blanc C, Gupta A, Gurjar BS, Saini H, Kotresh ST, Ali U, Bhatia D, Ohri A, Kumar M et al (2014) Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int 85(5):1151–1160. doi:10.1038/ki.2013.373
79. Strout MP, Seropian S, Berliner N (2010) Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis. Nat Rev Clin Oncol 7(7):415–420. doi:10.1038/nrclinonc.2010.40
80. Marsh RA, Allen CE, McClain KL, Weinstein JL, Kanter J, Skiles J, Lee ND, Khan SP, Lawrence J, Mo JQ, Bleesing JJ, Filipovich AH, Jordan MB (2013) Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer 60(1):101–109. doi:10.1002/pbc.24188
81. Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, Röth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM et al (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355(12):1233–1243. doi:10.1056/NEJMoa061648
82. Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, Mitchell LD, Cohen DR, Gregory WM, Hillmen P (2011) Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 117(25):6786–6792. doi:10.1182/blood-2011-02-333997
83. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T et al (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368(23):2169–2181. doi:10.1056/NEJMoa1208981
84. Liu L, Okada S, Kong X-F, Kreins AY, Cypowyj S, Abhyankar A, Toubiana J, Itan Y, Audry M, Nitschke P, Masson C, Toth B et al (2011) Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 208(8):1635–1648. doi:10.1084/jem.20110958
85. Higgins E, Al Shehri T, McAleer MA, Conlon N, Feighery C, Lilic D, Irvine AD (2015) Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol 135(2):551–553. doi:10.1016/j.jaci.2014.12.1867
86. Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Montealegre Sanchez GA, Tenbrock K, Wittkowski H, Jones OY, Kuehn HS, Lee CC, DeMattia MA et al (2014) Activated STING in a vascular and pulmonary syndrome. N Engl J Med 371(6):507–518. doi:10.1056/NEJMoa1312625
87. Das R, Guan P, Sprague L, Verbist K, Tedrick P, An QA, Cheng C, Kurachi M, Levine R, Wherry EJ, Canna SW, Behrens EM, Nichols KE (2016) Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood 127(13):1666–1675. doi:10.1182/blood-2015-12-684399
88. Li P, Huang P, Yang Y, Hao M, Peng H, Li F (2016) Updated understanding of autoimmune lymphoproliferative syndrome (ALPS). Clin Rev Allergy Immunol 50(1):55–63. doi:10.1007/s12016-015-8466-y
89. Rao VK (2015) Approaches to managing autoimmune cytopenias in novel immunological disorders with genetic underpinnings like autoimmune lymphoproliferative syndrome. Front Pediatr 3:65. doi:10.3389/fped.2015.00065
90. Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT (2016) Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood 127(1):17–28. doi:10.1182/blood-2015-07-657981
91. Bindl L, Torgerson T, Perroni L, Youssef N, Ochs HD, Goulet O, Ruemmele FM (2005) Successful use of the new immune-suppressor sirolimus in IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome). J Pediatr 147(2):256–259. doi:10.1016/j.jpeds.2005.04.017
92. Barzaghi F, Passerini L, Bacchetta R (2012) Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity. Front Immunol 3:211. doi:10.3389/fimmu.2012.00211
93. Bacchetta R, Barzaghi F, Roncarolo MG (2016) From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation. Ann N Y Acad Sci. doi:10.1111/nyas.13011
94. Angulo I, Vadas O, Garçon F, Banham-Hall E, Plagnol V, Leahy TR, Baxendale H, Coulter T, Curtis J, Wu C, Blake-Palmer K, Perisic O et al (2013) Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. Science 342(6160):866–871. doi:10.1126/science.1243292
95. Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, Avery DT, Moens L, Cannons JL, Biancalana M, Stoddard J, Ouyang W et al (2014) Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat Immunol 15(1):88–97. doi:10.1038/ni.2771
96. Harris J, Hartman M, Roche C, Zeng SG, O’Shea A, Sharp FA, Lambe EM, Creagh EM, Golenbock DT, Tschopp J, Kornfeld H, Fitzgerald KA et al (2011) Autophagy controls IL-1β secretion by targeting pro-IL-1β for degradation. J Biol Chem 286(11):9587–9597. doi:10.1074/jbc.M110.202911
97. Bigorgne AE, Farin HF, Lemoine R, Mahlaoui N, Lambert N, Gil M, Schulz A, Philippet P, Schlesser P, Abrahamsen TG, Oymar K, Davies EG et al (2014) TTC7A mutations disrupt intestinal epithelial apicobasal polarity. J Clin Invest 124(1):328–337. doi:10.1172/JCI71471
98. Gaspar HB, Aiuti A, Porta F, Candotti F, Hershfield MS, Notarangelo LD (2009) How I treat ADA deficiency. Blood 114(17):3524–3532. doi:10.1182/blood-2009-06-189209
99. Chan B, Wara D, Bastian J, Hershfield MS, Bohnsack J, Azen CG, Parkman R, Weinberg K, Kohn DB (2005) Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clin Immunol 117(2):133–143. doi:10.1016/j.clim.2005.07.006
100. Serana F, Sottini A, Chiarini M, Zanotti C, Ghidini C, Lanfranchi A, Notarangelo LD, Caimi L, Imberti L (2010) The different extent of B and T cell immune reconstitution after hematopoietic stem cell transplantation and enzyme replacement therapies in SCID patients with adenosine deaminase deficiency. J Immunol 185(12):7713–7722. doi:10.4049/jimmunol.1001770
101. Caccia S, Suffritti C, Cicardi M (2014) Pathophysiology of hereditary angioedema. Pediatr Allergy Immunol Pulmonol 27(4):159–163. doi:10.1089/ped.2014.0425
102. Krassilnikova S, Craig ET, Craig TJ (2010) Summary of the International Multicenter Prospective Angioedema C1-inhibitor Trials 1 and 2 (IMPACT1 and 2). Expert Rev Clin Immunol 6(3):327–334. doi:10.1586/eci.10.19
103. Lumry W, Manning ME, Hurewitz DS, Davis-Lorton M, Fitts D, Kalfus IN, Uknis ME (2013) Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. J Pediatr 162(5):1017–1022. doi:10.1016/j.jpeds.2012.11.030
104. Manson AL, Dempster J, Grigoriadou S, Buckland MS, Longhurst HJ (2014) Use of recombinant C1 inhibitor in patients with resistant or frequent attacks of hereditary or acquired angioedema. Eur J Dermatol 24(1):28–34. doi:10.1684/ejd.2013.2252
105. Li FY, Chaigne-Delalande B, Su H, Uzel G, Matthews H, Lenardo MJ (2014) XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus. Blood 123(14):2148–2152. doi:10.1182/blood-2013-11-538686
106. Chaigne-Delalande B, Li F-Y, O’Connor GM, Lukacs MJ, Jiang P, Zheng L, Shatzer A, Biancalana M, Pittaluga S, Matthews HF, Jancel TJ, Bleesing JJ et al (2013) Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. Science 341(6142):186–191. doi:10.1126/science.1240094
107. Fernandez-Boyanapalli R, Frasch SC, Riches DWH, Vandivier RW, Henson PM, Bratton DL (2010) PPARγ activation normalizes resolution of acute sterile inflammation in murine chronic granulomatous disease. Blood 116(22):4512–4522. doi:10.1182/blood-2010-02-272005
108. Fernandez-Boyanapalli RF, Frasch SC, Thomas SM, Malcolm KC, Nicks M, Harbeck RJ, Jakubzick CV, Nemenoff R, Henson PM, Holland SM, Bratton DL (2015) Pioglitazone restores phagocyte mitochondrial oxidants and bactericidal capacity in chronic granulomatous disease. J Allergy Clin Immunol 135(2):517–527. doi:10.1016/j.jaci.2014.10.034e12
109. Migliavacca M, Assanelli A, Ferrua F, Cicalese MP, Biffi A, Frittoli M, Silvani P, Chidini G, Calderini E, Mandelli A, Camporesi A, Milani R et al (2016) Pioglitazone as a novel therapeutic approach in chronic granulomatous disease. J Allergy Clin Immunol. doi:10.1016/j.jaci.2016.01.033
110. Dowdell KC, Pesnicak L, Hoffmann V, Steadman K, Remaley AT, Cohen JI, Straus SE, Rao VK (2009) Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas-deficient MRL/lpr(−/−) murine model of autoimmune lymphoproliferative syndrome (ALPS). Exp Hematol 37(4):487–494. doi:10.1016/j.exphem.2008.12.002
111. Bobé P, Bonardelle D, Benihoud K, Opolon P, Chelbi-Alix MK (2006) Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice. Blood 108(13):3967–3975. doi:10.1182/blood-2006-04-020610
112. Bajwa R, Savelli S, Gross T (2011) Pentostatin for treatment of refractory autoimmune lymphoproliferative syndrome. Pediatr Blood Cancer 57(2):336–337. doi:10.1002/pbc.23144
113. Shao BZ, Xu ZQ, Han BZ, Su DF, Liu C (2015) NLRP3 inflammasome and its inhibitors: a review. Front Pharmacol 6:262. doi:10.3389/fphar.2015.00262
114. Coll RC, Robertson AAB, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserra MC, Vetter I, Dungan LS, Monks BG, Stutz A, Croker DE, Butler MS et al (2015) A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 21(3):248–255. doi:10.1038/nm.3806
115. Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, D’Agostino D, Planavsky N, Lupfer C, Kanneganti TD, Kang S, Horvath TL et al (2015) The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med 21(3):263–269. doi:10.1038/nm.3804
116. MacGinnitie AJ (2014) Pediatric hereditary angioedema. Pediatr Allergy Immunol 25(5):420–427. doi:10.1111/pai.12168
117. Joseph K, Tholanikunnel BG, Bygum A, Ghebrehiwet B, Kaplan AP (2013) Factor XII-independent activation of the bradykinin-forming cascade: implications for the pathogenesis of hereditary angioedema types I and II. J Allergy Clin Immunol 132(2):470–475. doi:10.1016/j.jaci.2013.03.026
118. Wintenberger C, Boccon-Gibod I, Launay D, Fain O, Kanny G, Jeandel PY, Martin L, Gompel A, Bouillet L (2014) Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients. Clin Exp Immunol 178(1):112–117. doi:10.1111/cei.12379
119. Craig T, Aygören-Pürsün E, Bork K, Bowen T, Boysen H, Farkas H, Grumach A, Katelaris CH, Lockey R, Longhurst H, Lumry W, Magerl M et al (2012) WAO guideline for the management of hereditary angioedema. World Allergy Organ J 5(12):182–199. doi:10.1097/WOX.0b013e318279affa
120. Farkas H, Harmat G, Füst G, Varga L, Visy B (2002) Clinical management of hereditary angio-oedema in children. Pediatr Allergy Immunol 13(3):153–161
121. Vece TJ, Watkin LB, Nicholas SK, Canter D, Braun MC, Guillerman RP, Eldin KW, Bertolet G, McKinley SD, de Guzman M, Forbes LR, Chinn I et al (2016) Copa syndrome: a novel autosomal dominant immune dysregulatory disease. J Clin Immunol 36(4):377–387. doi:10.1007/s10875-016-0271-8